Key clinical point: Protein tyrosine phosphatase receptor gamma ( PTPRG), a tumor suppressor gene, could serve as a new biomarker to evaluate therapeutic response to tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML).
Major finding: In patients with CML, PTPRG expression was significantly lower at diagnosis vs. follow-up ( P less than .001). Patients with optimal response to TKI had significantly higher PTPRG expression during follow-up vs. diagnosis ( P less than .0005); however, no difference was observed in patients with a failed response to TKI ( P = .312).
Study details: This study assessed PTPRG expression in 21 patients with CML (chronic phase, n=18; accelerated phase, n=3) treated with imatinib (n=12) or nilotinib (n=9) and 7 healthy individuals.
Disclosures: This study was funded by the Qatar National Research Fund, and open access funding was enabled by the Qatar National Library. The authors declared no conflicts of interest.
Source: Ismail MA et al. Sci Rep. 2021 Apr 23. doi: 10.1038/s41598-021-86875-y .